½ÃÀ庸°í¼­
»óǰÄÚµå
1553666

´Ü¹éÁúüÇÐ ½ÃÀå ±Ô¸ð, Á¡À¯À² ¹× µ¿Ç⠺м® º¸°í¼­ : Á¦Ç° ¹× ¼­ºñ½ºº°, ±â¼úº°, ¿ëµµº°, Áö¿ªº°, ºÎ¹®º° ¿¹Ãø(2024-2030³â)

Proteomics Market Size, Share & Trends Analysis Report By Product & Service (Services, Reagents & Consumables, Instruments), By Technology (Spectrometry, Microarray Instruments), By Application, By Region, And Segment Forecasts, 2024 - 2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Grand View Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 120 Pages | ¹è¼Û¾È³» : 2-10ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

´Ü¹éÁúüÇÐ ½ÃÀåÀÇ ¼ºÀå°ú µ¿Çâ :

Grand View Research, Inc.ÀÇ ÃֽŠº¸°í¼­¿¡ µû¸£¸é, ¼¼°è ´Ü¹éÁúüÇÐ ½ÃÀå ±Ô¸ð´Â 2024³âºÎÅÍ 2030³â±îÁö 13.10%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)À» ±â·ÏÇÏ¿© 2030³â¿¡´Â 581¾ï 6,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

»ê¾÷ ¼ºÀåÀ» °¡¼ÓÇÏ´Â ÁÖ¿ä ¿äÀÎÀº °³ÀÎ ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, ´Ü¹éÁúüÇÐ Áú·® ºÐ¼®±â ¹× ¹ÙÀÌ¿ÀĨ Ç÷§ÆûÀ» Ȱ¿ëÇÑ Áø´Ü ÆÄÀÌÇÁ¶óÀÎÀÇ È®Àå, À¯ÀüüÇÐ ±â¹Ý ¹ß°ßÀÔ´Ï´Ù. ¶ÇÇÑ, ÀǾàǰ °³¹ß¿¡¼­ ´Ü¹éÁúüÇÐÀÇ Á߿伺À¸·Î ÀÎÇØ ¸¹Àº Á¦¾àȸ»çµéÀÌ ÀÚüÀûÀÎ ´Ü¹éÁúüÇÐ ºÎ¼­¸¦ ¼³¸³Çϰí ÀÖÀ¸¸ç, ÀÌ´Â Àü ¼¼°è »ê¾÷ È®Àå¿¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2021³â 9¿ù ¹ÙÀÌ¿À±×³ë½Ã½º(Biognosys)´Â ÀÓ»ó ¿¬±¸ ¹× ½Å¾à °³¹ß¿¡¼­ Â÷¼¼´ë ´Ü¹éÁúüÇРȰ¿ëÀ» ÃËÁøÇϱâ À§ÇØ ¿¡º¸ÅØ(Evotec)°úÀÇ Á¦ÈÞ¸¦ ¹ßÇ¥Çß½À´Ï´Ù.

Àü ¼¼°è ¿¬±¸ÀÚµéÀÌ SARS-CoV-2 ´Ü¹éÁúÀÇ 3D ±¸Á¶¸¦ ÇØµ¶ÇÏ´Â µ¥ ÁýÁßÇϰí ÀÖ´Â °¡¿îµ¥, Äڷγª19 »çÅ´ ¾÷°è¿¡ Å« ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹»óµÇ¸ç, °úÇÐÀÚµéÀº Äڷγª19¿¡ ´ëÇÑ È¿°úÀûÀÎ ÀǾàǰ ¹× »ý¹°ÇÐÀû Á¦Á¦¸¦ °³¹ßÇϱâ À§ÇØ ÀÌµé ´Ü¹éÁúÀÇ ½Äº° ±â¼ú, ±¸Á¶, Ư¼º, »óÈ£ÀÛ¿ëÀ» ¿¬±¸Çϰí ÀÖ½À´Ï´Ù. ¹ÙÀÌ·¯½º¿¡ ´ëÇÑ »õ·Ó°í È¿À²ÀûÀΠǥÀû Ä¡·áÁ¦¸¦ ã±â À§Çؼ­´Â ¹ÙÀÌ·¯½º ´Ü¹éÁúÀÇ ±¸Á¶¿Í ƯÁ¤ À§Ä¡¸¦ ÀÌÇØÇØ¾ß ÇÕ´Ï´Ù. µû¶ó¼­ Äڷγª19 Ä¡·áÁ¦ °³¹ß¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÏ¿© »ê¾÷ ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀÔ´Ï´Ù. ¶ÇÇÑ, ¸ÂÃãÇü ÀǾàǰ¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡·Î ÀÎÇÑ R&D ºñ¿ë Áõ°¡, ´Ü¹éÁúüÇÐ ±¸¼º ¿ä¼Ò¿¡ ´ëÇÑ ±â¼ú °³¹ßµµ ½ÃÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù.

¶ÇÇÑ, Áú·® ºÐ¼® ±â¹Ý ´Ü¹éÁúüÇÐ °³¼± ¹× ¹ÙÀÌ¿À¸¶Ä¿ ½Äº°°ú °ü·ÃµÈ À¯¸®ÇÑ ±âȸ·Î ÀÎÇØ ´Ü¹éÁúüÇÐ ½ÃÀåÀº ¸Å·ÂÀûÀÎ ½ÃÀå ¼ºÀå ÀáÀç·ÂÀ» °¡Áö°í ÀÖ½À´Ï´Ù. ÀÌ´Â ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀÔ´Ï´Ù. ÁÖ¿ä ¾÷°è Âü¿©ÀÚµéÀÌ »õ·Ó°Ô °³¼±µÈ ´Ü¹éÁúüÇÐ ±â¼úÀ» µµÀÔÇÏ¸é ¾÷°è ¼ºÀåÀ» ´õ¿í °¡¼ÓÈ­ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹¸¦ µé¾î, ºê·çÄ¿(Bruker Corp.)´Â 2017³â 9¿ù ¼¦°Ç ´Ü¹éÁúüÇп¡ ½Å¼ÓÇÑ µ¥ÀÌÅÍ ¼öÁýÀ» Á¦°øÇϱâ À§ÇØ PASEF(Parallel Accumulation And Serial Fragmentation) Áú·®ºÐ¼®À» À§ÇÑ timsTOF Pro ½Ã½ºÅÛÀ» Ãâ½ÃÇß½À´Ï´Ù. ¹ßÇ¥ÇÏ¿´½À´Ï´Ù. ÀÌ ½Ã½ºÅÛÀº µ¶ÀÚÀûÀÎ TIMS(Trapped Ion Mobility Spectrometry, Trapped Ion Mobility Spectrometry) ±â¼úÀ» »ç¿ëÇÕ´Ï´Ù. ¶ÇÇÑ, ´Ü¹éÁúüÇÐ ¿¬±¸ÀÇ ¹ßÀüÀ¸·Î ´Ü¹éÁú ¹ÙÀÌ¿À¸¶Ä¿ °ËÃâ, ´Ü¹éÁú ¹ÙÀÌ¿ÀĨ ¹× ¾àÈ¿´Ü¹éÁúüÇÐ, ´Ü¹éÁúüÇÐ ±â¹Ý ºÐÀÚÁø´ÜÀÌ °¡¼ÓÈ­µÇ°í ÀÖÀ¸¸ç, ÀÌ´Â ¸ðµÎ °³ÀÎ ¸ÂÃãÇü ÀÇ·á ¹ßÀü¿¡ Å©°Ô ±â¿©Çϰí ÀÖ½À´Ï´Ù.

´Ü¹éÁúüÇÐ ½ÃÀå º¸°í¼­ ÇÏÀ̶óÀÌÆ®

  • ¿¬±¸ Ȱµ¿ÀÇ È°¼ºÈ­¿Í È¿À²ÀûÀÎ ºÐ¼®À» À§ÇØ º¹ÀâÇÑ È¥ÇÕ¹°¿¡¼­ ´Ü¹éÁúÀ» ºÐ¸®ÇÏ·Á´Â ¼ö¿ä°¡ Áõ°¡ÇÔ¿¡ µû¶ó ½Ã¾à ¹× ¼Ò¸ðǰ Á¦Ç° ºÎ¹®ÀÌ 2023³â °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
  • ÀÓ»ó Áø´Ü ÀÀ¿ë ºÐ¾ß´Â Áúº´ÀÇ Á¶±â ¹ß°ß ¹× Áúº´ °ü¸®¸¦ À§ÇÑ Ã·´Ü Àü¹® °Ë»çÀÇ °³¹ß·Î 2023³â Å« Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.
  • ºÐ±¤ÇÐ ±â¼ú ºÎ¹®Àº µ¶¼º ¹ÝÀÀ ÇÁ·ÎÆÄÀϸµ, ±âÃÊ ºÐÀÚ»ý¹°ÇÐ, ¹ÙÀÌ¿À¸¶Ä¿ ½Äº°, ÀǾàǰ Ç¥Àû ½ºÅ©¸®´×¿¡ ´ëÇÑ »ç¿ë Áõ°¡·Î ÀÎÇØ 2023³â °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
  • ºÏ¹Ì´Â ¸ÂÃãÇü ÀǾàǰ¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, ¹Ì±¹¿¡¼­ »ç¾÷À» ¿î¿µÇÏ´Â ÁÖ¿ä ±â¾÷ÀÇ Á¸Àç, °íµµ·Î ¹ßÀüµÈ ÀÇ·á ¿¬±¸ ÇÁ·¹ÀÓ¿öÅ©, ¿¬±¸°³¹ß¿¡ ´ëÇÑ ¸·´ëÇÑ ÁöÃâ·Î ÀÎÇØ 2023³â ¼¼°è ¾÷°è¸¦ ÁÖµµÇß½À´Ï´Ù.
  • ¾Æ½Ã¾ÆÅÂÆò¾çÀº Ç¥Àû ÁúȯÀÇ À¯º´·ü Áõ°¡, °í·ÉÈ­ Àα¸ Áõ°¡, ´Ü¹éÁúüÇÐ µµÀÔ Áõ°¡ µîÀÇ ¿äÀÎÀ¸·Î ÀÎÇØ ¿¹Ãø ±â°£ µ¿¾È °¡Àå ³ôÀº CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ´Ü¹éÁúüÇÐ ½ÃÀå º¯¼ö, µ¿Çâ, ¹üÀ§

  • ½ÃÀå °èÅë Àü¸Á
    • »óÀ§ ½ÃÀå Àü¸Á
    • °ü·Ã/ºÎ¼ö ½ÃÀå Àü¸Á.
  • ½ÃÀå ¿ªÇÐ
    • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ ºÐ¼®
    • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ ºÐ¼®
  • ´Ü¹éÁúüÇÐ ½ÃÀå ºÐ¼® Åø
    • ¾÷°è ºÐ¼® - PorterÀÇ Five Forces ºÐ¼®
    • PESTEL ºÐ¼®
    • COVID-19ÀÇ ¿µÇ⠺м®

Á¦4Àå ´Ü¹éÁúüÇÐ ½ÃÀå : Á¦Ç° ¹× ¼­ºñ½ºº° ÃßÁ¤¡¤µ¿Ç⠺м®

  • ºÎ¹® ´ë½Ãº¸µå
  • ¼¼°èÀÇ ´Ü¹éÁúüÇÐ ½ÃÀå : Á¦Ç° ¹× ¼­ºñ½ºº° º¯µ¿ ºÐ¼®
  • ¼¼°èÀÇ ´Ü¹éÁúüÇÐ ½ÃÀå ±Ô¸ð¿Í µ¿Ç⠺м®, Á¦Ç° ¹× ¼­ºñ½ºº°, 2018-2030³â
  • ±â±â
  • ½Ã¾à ¹× ¼Ò¸ðǰ
  • ¼­ºñ½º

Á¦5Àå ´Ü¹éÁúüÇÐ ½ÃÀå : ¿ëµµº° ÃßÁ¤¡¤µ¿Ç⠺м®

  • ºÎ¹® ´ë½Ãº¸µå
  • ¼¼°èÀÇ ´Ü¹éÁúüÇÐ ½ÃÀå : ¿ëµµº° º¯µ¿ ºÐ¼®
  • ¼¼°èÀÇ ´Ü¹éÁúüÇÐ ½ÃÀå ±Ô¸ð¿Í µ¿Ç⠺м®, ¿ëµµº°, 2018-2030³â
  • Drug Discovery
  • ÀÓ»ó Áø´Ü
  • ±âŸ

Á¦6Àå ´Ü¹éÁúüÇÐ ½ÃÀå : ±â¼úº° ÃßÁ¤¡¤µ¿Ç⠺м®

  • ºÎ¹® ´ë½Ãº¸µå
  • ¼¼°èÀÇ ´Ü¹éÁúüÇÐ ½ÃÀå : ±â¼úº° º¯µ¿ ºÐ¼®
  • ¼¼°èÀÇ ´Ü¹éÁúüÇÐ ½ÃÀå ±Ô¸ð¿Í µ¿Ç⠺м®, ±â¼úº°, 2018-2030³â
  • Â÷¼¼´ë ½ÃÄö½Ì
  • ¸¶ÀÌÅ©·Î¾î·¹ÀÌ ±â±â
  • X¼± °áÁ¤ ±¸Á¶ ºÐ¼®
  • ºÐ±¤ ÃøÁ¤
  • Å©·Î¸¶Åä±×·¡ÇÇ
  • ´Ü¹éÁú ºÐȹ ½Ã½ºÅÛ
  • Àü±â¿µµ¿
  • Ç¥¸é ÇöóÁ °ø¸í(SPR) ½Ã½ºÅÛ
  • ±âŸ ±â¼ú

Á¦7Àå ´Ü¹éÁúüÇÐ ½ÃÀå : Áö¿ªº° ÃßÁ¤¡¤µ¿Ç⠺м®

  • Áö¿ªº° ½ÃÀå Á¡À¯À² ºÐ¼®, 2023³â ¹× 2030³â
  • Áö¿ª ½ÃÀå ´ë½Ãº¸µå
  • ½ÃÀå ±Ô¸ð, ¿¹Ãø µ¿Ç⠺м®, 2018-2030³â :
  • ºÏ¹Ì
    • ºÏ¹Ì ½ÃÀå Ã߻ꡤ¿¹Ãø 2018-2030³â
    • ¹Ì±¹
    • ij³ª´Ù
    • ¸ß½ÃÄÚ
  • À¯·´
    • 2018³âºÎÅÍ 2030³â±îÁö À¯·´ ½ÃÀå Ã߻ꡤ¿¹Ãø
    • ¿µ±¹
    • µ¶ÀÏ
    • ÇÁ¶û½º
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • ³ë¸£¿þÀÌ
    • ½º¿þµ§
    • µ§¸¶Å©
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀå Ã߻ꡤ¿¹Ãø 2018-2030³â
    • ÀϺ»
    • Áß±¹
    • Àεµ
    • È£ÁÖ
    • Çѱ¹
    • ű¹
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ¶óƾ¾Æ¸Þ¸®Ä« ½ÃÀå Ã߻ꡤ¿¹Ãø 2018-2030³â
    • ºê¶óÁú
    • ¾Æ¸£ÇîÆ¼³ª
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« ½ÃÀå Ã߻ꡤ¿¹Ãø 2018³âºÎÅÍ 2030³â
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
    • Äí¿þÀÌÆ®

Á¦8Àå °æÀï ±¸µµ

  • ±â¾÷/°æÀï ºÐ·ù
  • Àü·« ¸ÅÇÎ
  • ±â¾÷ ½ÃÀå ÇöȲ ºÐ¼®, 2023³â
  • ±â¾÷ °³¿ä/»óÀå±â¾÷
    • Illumina Inc.
    • Agilent Technologies Inc.
    • Bio-Rad Laboratories, Inc.
    • Thermo Fisher Scientific, Inc.
    • Bruker Corporation
    • F. Hoffmann-La Roche Ltd.
    • Waters Corporation
    • Merck KGaA
    • Danaher
    • Standard BioTools Inc.
LSH 24.09.26

Proteomics Market Growth & Trends:

The global proteomics market size is expected to reach USD 58.16 billion by 2030, registering a CAGR of 13.10% from 2024 to 2030, according to a new report by Grand View Research, Inc. The major factors driving the industry growth are a rise in the demand for personalized medicine, an expansion of the pipeline of diagnostics utilizing proteomics mass spectrometry as well as biochip platforms, and discoveries based on genomics. Moreover, owing to the importance of proteomics in drug development, numerous pharmaceutical companies have established their own proteomic divisions, which are fueling the expansion of the global industry. For instance, in September 2021, Biognosys, announced the collaboration with Evotec, to promote the use of next-generation proteomics in clinical research and drug discovery.

The COVID-19 outbreak is expected to have a significant impact on the industry, as researchers across the world are concentrating on decoding 3D structures of SARS-CoV-2 proteins. To create effective medications and biological products against COVID-19, scientists are also attempting to examine the identification techniques, structures, characterization, and interactions of these proteins. The protein structure of virus proteins and their specific locations must be understood to find a novel, efficient target treatment medication for a virus. Therefore, it will increase the demand for drug development for COVID-19 and propel industry growth. The growing need for customized medications increased R&D spending, and technological developments related to proteomics components are also driving the market.

In addition, attractive market expansion potential for proteomics is anticipated to come from improvements in mass spectrometry-based proteomics and lucrative opportunities related to biomarker identification. Thereby, propelling the market growth. The introduction of new and improved proteomics techniques by major industry participants is projected to further accelerate the growth of the industry. For instance, to provide quick data acquisition for shotgun proteomics, Bruker Corp. introduced the timsTOF Pro system for Parallel Accumulation And Serial Fragmentation (PASEF) mass spectrometry in September 2017. This system uses proprietary Trapped Ion Mobility Spectrometry (TIMS) technology. Furthermore, proteomic research advancements have accelerated the detection of protein biomarkers, protein biochips & pharmacoproteomics, and proteomics-based molecular diagnostics, which have all made significant contributions to the development of personalized medicine.

Proteomics Market Report Highlights:

  • The reagent & consumables product segment held the largest share in 2023 due to rising research activities and the growing demand for protein separation from complicated mixtures for efficient analysis
  • The clinical diagnostics application segment held a larger share in 2023 due to the development of sophisticated & specialized tests for early disease detection and disease management
  • The spectroscopy technology segment held the maximum share in 2023 owing to the increasing usage in toxicological response profiling, basic molecular biology, biomarker identification, and pharmaceutical target screening
  • North America led the global industry in 2023 due to a rise in demand for personalized drugs, the existence of major players operating in the U.S. and a highly developed healthcare research framework, and substantial expenditure on R&D
  • Asia Pacific is expected to grow at the highest CAGR over the projected period due to factors, such as the rising prevalence of target diseases, increasing aging population, and rising proteomics adoption

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definitions
    • 1.2.1. Product & Service Segment
    • 1.2.2. Application Segment
    • 1.2.3. Technology Segment
  • 1.3. Information analysis
    • 1.3.1. Market formulation & data visualization
  • 1.4. Data validation & publishing
  • 1.5. Information Procurement
    • 1.5.1. Primary Research
  • 1.6. Information or Data Analysis
  • 1.7. Market Formulation & Validation
  • 1.8. Market Model
  • 1.9. Total Market: CAGR Calculation
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Insights Landscape

Chapter 3. Proteomics Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook.
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Rising prevalence of chronic and infectious diseases
      • 3.2.1.2. Growing preference for personalized medicine
      • 3.2.1.3. Technological advancements in proteomics techniques
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High cost of proteomics tools and instruments
  • 3.3. Proteomics Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Proteomics Market: Product & Service Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Global Proteomics Market Product & Service Movement Analysis
  • 4.3. Global Proteomics Market Size & Trend Analysis, by Product & Service, 2018 to 2030 (USD Million)
  • 4.4. Instruments
    • 4.4.1. Instruments market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5. Reagents & Consumables
    • 4.5.1. Reagents & consumables market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6. Services
    • 4.6.1. Services market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Proteomics Market: Application Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Global Proteomics Market Application Movement Analysis
  • 5.3. Global Proteomics Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
  • 5.4. Drug Discovery
    • 5.4.1. Drug discovery market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5. Clinical Diagnostics
    • 5.5.1. Clinical diagnostics market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6. Others
    • 5.6.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Proteomics Market: Technology Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Global Proteomics Market Technology Movement Analysis
  • 6.3. Global Proteomics Market Size & Trend Analysis, by Technology, 2018 to 2030 (USD Million)
  • 6.4. Next-generation Sequencing
    • 6.4.1. Next-generation sequencing market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. Microarray Instruments
    • 6.5.1. Microarray instruments market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. X-ray Crystallography
    • 6.6.1. X-ray crystallography market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7. Spectrometry
    • 6.7.1. Spectrometry market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.8. Chromatography
    • 6.8.1. Chromatography market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.9. Protein Fractionation Systems
    • 6.9.1. Protein fractionation systems market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.10. Electrophoresis
    • 6.10.1. Electrophoresis market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.11. Surface Plasma Resonance (SPR) Systems
    • 6.11.1. Surface plasma resonance (SPR) systems market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.12. Other Technologies
    • 6.12.1. Other technologies market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Proteomics Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2023 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 7.4. North America
    • 7.4.1. North America market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.2. U.S.
      • 7.4.2.1. Key country dynamics
      • 7.4.2.2. Competitive scenario
      • 7.4.2.3. Regulatory framework
      • 7.4.2.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.3. Canada
      • 7.4.3.1. Key country dynamics
      • 7.4.3.2. Competitive scenario
      • 7.4.3.3. Regulatory framework
      • 7.4.3.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.4. Mexico
      • 7.4.4.1. Key country dynamics
      • 7.4.4.2. Competitive scenario
      • 7.4.4.3. Regulatory framework
      • 7.4.4.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5. Europe
    • 7.5.1. Europe market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.2. UK
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Competitive scenario
      • 7.5.2.3. Regulatory framework
      • 7.5.2.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.3. Germany
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Competitive scenario
      • 7.5.3.3. Regulatory framework
      • 7.5.3.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.4. France
      • 7.5.4.1. Key country dynamics
      • 7.5.4.2. Competitive scenario
      • 7.5.4.3. Regulatory framework
      • 7.5.4.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.5. Italy
      • 7.5.5.1. Key country dynamics
      • 7.5.5.2. Competitive scenario
      • 7.5.5.3. Regulatory framework
      • 7.5.5.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.6. Spain
      • 7.5.6.1. Key country dynamics
      • 7.5.6.2. Competitive scenario
      • 7.5.6.3. Regulatory framework
      • 7.5.6.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.7. Norway
      • 7.5.7.1. Key country dynamics
      • 7.5.7.2. Competitive scenario
      • 7.5.7.3. Regulatory framework
      • 7.5.7.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.8. Sweden
      • 7.5.8.1. Key country dynamics
      • 7.5.8.2. Competitive scenario
      • 7.5.8.3. Regulatory framework
      • 7.5.8.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.9. Denmark
      • 7.5.9.1. Key country dynamics
      • 7.5.9.2. Competitive scenario
      • 7.5.9.3. Regulatory framework
      • 7.5.9.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Asia Pacific
    • 7.6.1. Asia Pacific market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.2. Japan
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Competitive scenario
      • 7.6.2.3. Regulatory framework
      • 7.6.2.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.3. China
      • 7.6.3.1. Key country dynamics
      • 7.6.3.2. Competitive scenario
      • 7.6.3.3. Regulatory framework
      • 7.6.3.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.4. India
      • 7.6.4.1. Key country dynamics
      • 7.6.4.2. Competitive scenario
      • 7.6.4.3. Regulatory framework
      • 7.6.4.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.5. Australia
      • 7.6.5.1. Key country dynamics
      • 7.6.5.2. Competitive scenario
      • 7.6.5.3. Regulatory framework
      • 7.6.5.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.6. South Korea
      • 7.6.6.1. Key country dynamics
      • 7.6.6.2. Competitive scenario
      • 7.6.6.3. Regulatory framework
      • 7.6.6.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.7. Thailand
      • 7.6.7.1. Key country dynamics
      • 7.6.7.2. Competitive scenario
      • 7.6.7.3. Regulatory framework
      • 7.6.7.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7. Latin America
    • 7.7.1. Latin America market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.2. Brazil
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Competitive scenario
      • 7.7.2.3. Regulatory framework
      • 7.7.2.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.3. Argentina
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Competitive scenario
      • 7.7.3.3. Regulatory framework
      • 7.7.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.8. MEA
    • 7.8.1. MEA market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.8.2. South Africa
      • 7.8.2.1. Key country dynamics
      • 7.8.2.2. Competitive scenario
      • 7.8.2.3. Regulatory framework
      • 7.8.2.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.8.3. Saudi Arabia
      • 7.8.3.1. Key country dynamics
      • 7.8.3.2. Competitive scenario
      • 7.8.3.3. Regulatory framework
      • 7.8.3.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.8.4. UAE
      • 7.8.4.1. Key country dynamics
      • 7.8.4.2. Competitive scenario
      • 7.8.4.3. Regulatory framework
      • 7.8.4.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.8.5. Kuwait
      • 7.8.5.1. Key country dynamics
      • 7.8.5.2. Competitive scenario
      • 7.8.5.3. Regulatory framework
      • 7.8.5.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Company/Competition Categorization
  • 8.2. Strategy Mapping
  • 8.3. Company Market Position Analysis, 2023
  • 8.4. Company Profiles/Listing
    • 8.4.1. Illumina Inc.
      • 8.4.1.1. Company overview
      • 8.4.1.2. Financial performance
      • 8.4.1.3. Product/Service benchmarking
      • 8.4.1.4. Strategic initiatives
    • 8.4.2. Agilent Technologies Inc.
      • 8.4.2.1. Company overview
      • 8.4.2.2. Financial performance
      • 8.4.2.3. Product/Service benchmarking
      • 8.4.2.4. Strategic initiatives
    • 8.4.3. Bio-Rad Laboratories, Inc.
      • 8.4.3.1. Company overview
      • 8.4.3.2. Financial performance
      • 8.4.3.3. Product/Service benchmarking
      • 8.4.3.4. Strategic initiatives
    • 8.4.4. Thermo Fisher Scientific, Inc.
      • 8.4.4.1. Company overview
      • 8.4.4.2. Financial performance
      • 8.4.4.3. Product/Service benchmarking
      • 8.4.4.4. Strategic initiatives
    • 8.4.5. Bruker Corporation
      • 8.4.5.1. Company overview
      • 8.4.5.2. Financial performance
      • 8.4.5.3. Product/Service benchmarking
      • 8.4.5.4. Strategic initiatives
    • 8.4.6. F. Hoffmann-La Roche Ltd.
      • 8.4.6.1. Company overview
      • 8.4.6.2. Financial performance
      • 8.4.6.3. Product/Service benchmarking
      • 8.4.6.4. Strategic initiatives
    • 8.4.7. Waters Corporation
      • 8.4.7.1. Company overview
      • 8.4.7.2. Financial performance
      • 8.4.7.3. Product/Service benchmarking
      • 8.4.7.4. Strategic initiatives
    • 8.4.8. Merck KGaA
      • 8.4.8.1. Company overview
      • 8.4.8.2. Financial performance
      • 8.4.8.3. Product/Service benchmarking
      • 8.4.8.4. Strategic initiatives
    • 8.4.9. Danaher
      • 8.4.9.1. Company overview
      • 8.4.9.2. Financial performance
      • 8.4.9.3. Product/Service benchmarking
      • 8.4.9.4. Strategic initiatives
    • 8.4.10. Standard BioTools Inc.
      • 8.4.10.1. Company overview
      • 8.4.10.2. Financial performance
      • 8.4.10.3. Product/Service benchmarking
      • 8.4.10.4. Strategic initiatives
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦